abrdn Healthcare Opportunities Fund Shares of Beneficial Interest (THQ)

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at abrdn Healthcare Opportunities Fund as a closed-end fund, not an operating company, so my first question is whether the assets and distribution are sound. The stated 11.38% dividend yield is the main attraction, but a high yield is not a margin of safety by itself; I would need evidence that investment returns cover it, and the data provided does not give coverage. At the 2026-10-16 close of $17.93, FairStock calculates a P/E of -25.61, so the provided earnings figure is negative. The price sits inside the 52-week range of $16.28 to $20.39, closer to the middle than either extreme. FairStock's Piotroski F-score is 0/9, which offers no sign of financial improvement, while its Altman Z-score of 2.01 is a moderate reading, not a clear distress signal. I cannot assess book value, returns on equity or capital, leverage, revenue, profit growth, or a Lynch category: P/B, ROE, ROCE, D/E and growth are not available, and the Lynch category is none because only 0 years of annual results are filed. The healthcare mandate and balanced equity/fixed-income approach are understandable, but without NAV, discount or premium, and distribution coverage, I cannot call the price cheap. This looks like a high-yield fund whose current numbers require more proof before it deserves a margin-of-safety price.

In plain English: The fund owns healthcare shares and bonds and pays a high income yield. The figures show it is losing money and has little filed history, so it looks weak on the data given. At $17.93, the price is hard to call cheap or expensive because earnings are negative and no usable accounting value is given.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-16 close · note generated 2026-10-20 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer